Výsledky vyhledávání - "H. A. Burris"

Abstract P6-18-11: Long-term responders to single-agent margetuximab, an Fc-modified anti-HER2 monoclonal antibody, in metastatic HER2+ breast cancer patients with prior anti-HER2 therapy

Autor: S-A Im, Hua Li, Paul A. Moore, Y-J. Bang, Jeffrey L. Nordstrom, Giuseppe Giaccone, D-Y. Oh, Edwin P. Rock, Todd M. Bauer, Jan Baughman, Shengyan Hong, H. A. Burris

Publikováno v: Cancer Research. 79:P6-18

Background Margetuximab is an Fc-optimized anti-HER2 antibody that recognizes the same epitope as trastuzumab. Margetuximab has increased affinity for the activating CD16A Fc-receptor on NK cells and macrophages as well as decreased affinity for the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8db29e792765184248f5f9b602f985a4
https://doi.org/10.1158/1538-7445.sabcs18-p6-18-11

Zobrazit plný text záznamu

Abstract P6-18-15: Ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis

Autor: Debu Tripathy, S-A Im, Aditya Bardia, Francisco J. Esteva, M. Campone, S Chia, W Bao, O Kong, Andrew T. Chan, D. A. Yardley, I Diaz-Padilla, H. A. Burris, K Rodriguez Lorenc

Publikováno v: Cancer Research. 79:P6-18

Background: In Phase III trials, ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + various endocrine therapy (ET) partners has demonstrated significantly prolonged progression-free survival vs placebo (PBO) + ET in patients (pts) with hormone

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6ee45ff9687858c60888e7104124bdd6
https://doi.org/10.1158/1538-7445.sabcs18-p6-18-15

Zobrazit plný text záznamu

Abstract P6-17-35: Withdrawn

Autor: Erika Hamilton, Johanna C. Bendell, Aditya Bardia, Muralidhar Beeram, H. A. Burris, Minal A. Barve, Anthony W. Tolcher, William Jeffery Edenfield, Anne M. Noonan, J Xu, Hatem Soliman, E Hailman, Rebecca Mosher

Publikováno v: Cancer Research. 79:P6-17

This abstract was withdrawn by the authors. Citation Format: Hamilton EP, Barve M, Bardia A, Beeram M, Edenfield WJ, Noonan A, Tolcher A, Bendell J, Mosher R, Xu J, Hailman E, Burris III H, Soliman HH. Withdrawn [abstract]. In: Proceedings of the 201

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3c4956cfc716d7a6cf22b4cab65e6284
https://doi.org/10.1158/1538-7445.sabcs18-p6-17-35

Zobrazit plný text záznamu

Abstract P6-18-07: Ribociclib + endocrine therapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer presenting with visceral metastases: Subgroup analysis of phase III MONALEESA trials

Autor: Francisco J. Esteva, Andrew T. Chan, O Kong, Paul Wheatley-Price, Arnd Nusch, Y-S Yap, DJ Slamon, H. A. Burris, K Rodriguez Lorenc, D. A. Yardley, A Gaur, I Diaz-Padilla, Thomas Bachelot, Gabe S. Sonke

Publikováno v: Cancer Research. 79:P6-18

Background: Patients (pts) with advanced breast cancer (ABC) who present with visceral metastases (mets) have a poorer prognosis vs pts with non-visceral disease. In the Phase III MONALEESA (ML) trials, ribociclib (RIB) + endocrine therapy (ET) prolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2c48b2b80403c4298f7e499fcb2fd7fb
https://doi.org/10.1158/1538-7445.sabcs18-p6-18-07

Zobrazit plný text záznamu

JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions

Autor: Yuko Kitagawa, Takayuki Yoshino, J.-Y. Douillard, H. A. Burris, Ashish Saxena, F. Calvo, Saori Mishima, Masayuki Takeda, J. Tabernero, Yasuhiro Kodera, Eishi Baba, Hiroya Taniguchi, Michael J. Overman, K.-H. Yeh, Georgios Pentheroudakis, Andrés Cervantes, Yoichi Naito, L.-T. Chen, Kensaku Yoshida

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname

A Japan Society of Clinical Oncology (JSCO)-hosted expert meeting was held in Japan on 27 October 2019, which comprised experts from the JSCO, the Japanese Society of Medical Oncology (JSMO), the European Society for Medical Oncology (ESMO), the Amer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6770459c670c1d539cd87fdb9bfe9700
https://pubmed.ncbi.nlm.nih.gov/32272210

Zobrazit plný text záznamu

Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study

Autor: John D. Hainsworth, Hyunseok Kang, Christopher Sweeney, Funda Meric-Bernstam, H. A. Burris, Steven Blotner, Vaikunth Cuchelkar, Ron Bose, Charles Swanton, Daniel W. Bowles, Razelle Kurzrock, David R. Spigel, Michael S. Beattie, Katja Schulze

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology, vol 31, iss 3

BackgroundSystemic therapy options for salivary cancers are limited. MyPathway (NCT02091141), a phase IIa study, evaluates targeted therapies in non-indicated tumor types with actionable molecular alterations. Here, we present the efficacy and safety

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15c0569b0fcae5931a8b426124c402c9

Zobrazit plný text záznamu

Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer

Publikováno v: Cancer Research. 78:PD3-14

Background LIV-1, a transmembrane protein and downstream target of STAT3, is highly expressed in breast cancer cells. It is associated with lymph node involvement and metastatic progression. SGN-LIV1A is an anti-LIV-1 antibody conjugated via a protea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::59f9b2732d7c4da95ba6b598588baf19
https://doi.org/10.1158/1538-7445.sabcs17-pd3-14

Zobrazit plný text záznamu

Abstract P5-21-18: Subsequent treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received ribociclib + letrozole vs placebo + letrozole in the phase III MONALEESA-2 study

Autor: Pierfranco Conte, H. A. Burris, JT Beck, K. L. Blackwell, K. Petrakova, Sibel Blau, M. Miller, M Monaco, Santosh Sutradhar, M. Campone, A.M. Favret, Shani Paluch-Shimon

Publikováno v: Cancer Research. 78:P5-21

Background: In the Phase III MONALEESA-2 study (NCT01958021), ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor [CDK4/6i]) + letrozole (LET) significantly prolonged progression-free survival (PFS) vs placebo (PBO) + LET in postmenopausal women w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0685bee32db1136bb8208553098875a6
https://doi.org/10.1158/1538-7445.sabcs17-p5-21-18

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání